Search
                    Pulmonary Fibrosis Paid Clinical Trials in Indiana
A listing of 5  Pulmonary Fibrosis  clinical trials  in Indiana  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 5 of 5
        
        
    
                The state of Indiana currently has 5 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville. 
            
                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.             
        
        
    Gender:
                ALL
            Ages:
                21 years and above
            Trial Updated:
                08/20/2025
            
            Locations: Local Institution - 0441, Indianapolis, Indiana         
        
        
            Conditions: Progressive Pulmonary Fibrosis
        
            
        
    
                
                                    A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
                                
            
            
        Recruiting
                            
            
                The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Cohort 1 has com...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 85 years
            Trial Updated:
                08/08/2025
            
            Locations: IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine, Muncie, Indiana         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
        
            
        
    
                
                                    A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/07/2025
            
            Locations: Local Institution - 0190, Indianapolis, Indiana         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
                                
            
            
        Recruiting
                            
            
                Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/05/2025
            
            Locations: Indiana University Health, Indianapolis, Indiana         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    A Study to Investigate Leramistat in Patients With IPF
                                
            
            
        Recruiting
                            
            
                To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                02/16/2024
            
            Locations: IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine, Muncie, Indiana         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    1 - 5 of 5
            
            
        